Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Participants were randomly assigned to one of five therapies: exenatide alone, dapagliflozin alone, dual therapy of exenatide and dapagliflozin, combined dapagliflozin and metformin therapy, or the weight-loss medication phentermine/topiramate extended-release
9.Certification: cGMP,KOSHER,HALAL,BRC,ORGANIC,ISO9001,ISO22000 etc
Factors favoring combination therapy Type 2 diabetes not controlled on basal insulin alone
& Reid, L
doi:10.1007/s10815-020-01836-0
US$ 27.80
US$ 27.61
US$ 21.01
